These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1525605)

  • 1. Alloengraftment in IL-2-treated mice.
    Sykes M; Pearson DA
    Bone Marrow Transplant; 1992 Aug; 10(2):157-63. PubMed ID: 1525605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M; Bukhari Z; Sachs DH
    Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the anti-GVHD effect of IL-2. I. Protective host-type cell populations are not induced by IL-2 treatment alone.
    Abraham VS; Sykes M
    Bone Marrow Transplant; 1991; 7 Suppl 1():29-32. PubMed ID: 2043882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
    Sykes M; Chester CH; Sundt TM; Romick ML; Hoyles KA; Sachs DH
    J Immunol; 1989 Dec; 143(11):3503-11. PubMed ID: 2584703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
    Abraham VS; Sachs DH; Sykes M
    J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
    Sykes M; Sheard M; Sachs DH
    J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.
    Sykes M
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():30-3. PubMed ID: 2534057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M; Sharabi Y; Sachs DH
    Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
    J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.
    Chester CH; Sykes M; Sachs DH
    Bone Marrow Transplant; 1989 Mar; 4(2):195-200. PubMed ID: 2650790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2-induced GVHD protection is not inhibited by cyclosporine and is maximal when IL-2 is given over a 25 h period beginning on the day following bone marrow transplantation.
    Sykes M; Pearson DA; Szot GL
    Bone Marrow Transplant; 1995 Mar; 15(3):395-9. PubMed ID: 7599564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.